Harbour Investments Inc. Lowers Stock Holdings in Hims & Hers Health, Inc. $HIMS

Harbour Investments Inc. reduced its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 87.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,823 shares of the company’s stock after selling 32,162 shares during the period. Harbour Investments Inc.’s holdings in Hims & Hers Health were worth $157,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the third quarter worth $28,000. Silicon Valley Capital Partners purchased a new position in Hims & Hers Health in the third quarter valued at $48,000. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health in the fourth quarter valued at $28,000. Bogart Wealth LLC boosted its holdings in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 2.1%

Shares of NYSE HIMS opened at $28.08 on Friday. The company has a market capitalization of $6.50 billion, a price-to-earnings ratio of -311.99, a price-to-earnings-growth ratio of 51.61 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The business has a 50-day moving average of $24.50 and a two-hundred day moving average of $27.09. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm earned $0.20 earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the sale, the chief operating officer owned 407,282 shares in the company, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the sale, the insider owned 299,368 shares in the company, valued at $8,981,040. This trade represents a 3.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 212,807 shares of company stock worth $5,473,644 over the last three months. 11.76% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Citigroup lifted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. UBS Group set a $23.00 target price on Hims & Hers Health in a report on Friday, May 22nd. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. TD Cowen decreased their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a report on Friday, March 27th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.70.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.